Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.55 |
| ▸ | FPR2 | P25090 | 2/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.43 |
| ▸ | C5 | P01031 | 2/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | QPCT | Q16769 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13397957 | 0.85 | PSEN1 (0.54) | FPR2 | |
| SCHEMBL14870571 | 0.82 | PSEN1 (0.52) | AAK1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL4449706 | 0.77 | AAK1 (0.65) | AAK1CYP19A1CYP11B1CYP11B2QPCT | |
| SCHEMBL3313160 | 0.73 | AAK1 (0.53) | AAK1CYP19A1CYP11B1CYP11B2QPCT | |
| SCHEMBL3319364 | 0.73 | AAK1 (0.53) | AAK1CYP19A1CYP11B1CYP11B2QPCT | |
| SCHEMBL3314736 | 0.73 | PSEN1 (0.54) | FPR2ROCK2ROCK1 | |
| SCHEMBL3314797 | 0.73 | PSEN1 (0.54) | FPR2ROCK2ROCK1 | |
| SCHEMBL13972296 | 0.72 | PSEN1 (0.41) | FPR2ROCK2ROCK1QPCT | |
| SCHEMBL3316441 | 0.71 | KMT2A (0.56) | AAK1 | |
| SCHEMBL17783138 | 0.71 | AAK1 (1.00) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105904-A1 | UREA TYPE CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105904-A1 | UREA TYPE CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105904-A1 | UREA TYPE CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2019093-A1 | UREA TYPE CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105904-A1 | UREA TYPE CINNAMIDE DERIVATIVE | SLC14A1, UTS2R, MAN2B1 | AAK1 2344/4885FPR2 3050/4885CYP19A1 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.